文献速递白血病

G3BP2通过稳定ELF1介导的MCL1转录赋予急性髓系白血病维奈克拉耐药

G3BP2 confers venetoclax resistance by stabilizing ELF1-mediated MCL1 transcription in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2026-07-20

该研究探讨RNA结合蛋白G3BP2在急性髓系白血病(AML)维奈克拉耐药中的作用。整合分析显示G3BP2赋予维奈克拉耐药并与不良预后相关;G3BP2通过结合ELF1 mRNA增强其稳定性,进而促进ELF1结合MCL1启动子诱导MCL1表达。C108抑制G3BP2联合维奈克拉在原代AML细胞和PDX中显示抗癌效果并延长AML模型小鼠总生存期。

要点

  • G3BP2在AML中赋予维奈克拉耐药并与不良预后相关
  • G3BP2通过稳定ELF1 mRNA上调MCL1转录而非直接结合MCL1
  • C108抑制G3BP2联合维奈克拉可增强疗效并延长模型小鼠生存

核心结论

  • G3BP2通过ELF1介导的MCL1转录调控维奈克拉耐药,提示新的治疗策略。

研究设计与样本

  • 研究采用整合分析、AML细胞实验、异种移植小鼠及PDX模型评估G3BP2功能与药物联合效果。

主要发现

  • G3BP2缺失抑制AML增殖并诱导AML细胞和异种移植小鼠凋亡。
  • G3BP2表达与多个AML队列中MCL1水平一致,且G3BP2对MCL1的调控在AML细胞中得到验证。
  • G3BP2与MCL1不直接互作,而是与ELF1 mRNA互作增加其稳定性。
  • 转录因子ELF1结合MCL1启动子诱导其表达,G3BP2抑制可减弱该效应。
  • C108介导的G3BP2抑制联合维奈克拉在原代AML细胞和PDX中具有抗癌作用,并延长AML模型小鼠总生存期。

临床怎么用

  • G3BP2可作为维奈克拉耐药AML的潜在治疗靶点,C108联合维奈克拉策略值得进一步临床转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venetoclax is a promising treatment for acute myeloid leukemia (AML) patients, but resistance occurs following the upregulation of MCL1. The RNA-binding protein G3BP2 is upregulated in various solid tumors, and targeting G3BP2 has been shown to restore chemosensitivity. However, the role of G3BP2 in AML development and venetoclax resistance remains unknown. Herein, an integrated analysis revealed that G3BP2 confers venetoclax resistance and correlates with poor outcomes in AML. G3BP2 deficiency inhibits AML proliferation and induces apoptosis in AML cells and xenograft mice. G3BP2 expression aligns with MCL1 levels across AML cohorts, and the regulatory effect of G3BP2 on MCL1 was validated in AML cells. Notably, G3BP2 and MCL1 do not interact directly; instead, G3BP2 interacts with ELF1 mRNA to increase its stability. The transcription factor ELF1 binds to the MCL1 promoter to induce its expression, which can be attenuated by G3BP2 inhibition. Furthermore, C108-mediated inhibition of G3BP2, in combination with venetoclax, has anticancer effects in primary AML cells and in patient-derived xenografts (PDX). C108 increases the therapeutic efficacy of venetoclax and their combination prolongs overall survival (OS) in AML model mice. These findings identify G3BP2 as a regulator of venetoclax resistance through ELF1-mediated MCL1 transcription, suggesting new therapeutic strategies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Chen Z, Cai Y, Wang Y, et al. G3BP2 confers venetoclax resistance by stabilizing ELF1-mediated MCL1 transcription in acute myeloid leukemia. Leukemia. 2026. PMID: 42477086. doi:10.1038/s41375-026-03063-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。